To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Sunlenca

Lenacapavir
Antiviral
Subcutaneous Solution
Approval Date
22-Dec-22
NCE-1 Date
22-Dec-26
NCE Date
22-Dec-27
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
1151
2027
2291
2028
3676
2029
5013
2030
6202
2031
7222
2032
8094
Molecule profile

Details & specifications

Molecule
Lenacapavir
Innovator
GILEAD SCIENCES, INC.
Dosage Form
Subcutaneous Solution
Strength
EQ 463.5 mg base/1.5 mL (EQ 309 mg base/mL)
Therapeutic Category
Antiviral
Usage
To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations
Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data
Milestones tracked against primary FDA sources and refreshed continuously.
Analyst-built projections
Seven-year sales outlooks modeled by our pharma intelligence team.
First-to-file focus
Exclusivity windows framed around the decisions generics teams actually make.
Partnership on demand
From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?